NCT02944565View on ClinicalTrials.gov

Daratumumab in Treating Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

July 20, 2017

Study Completion Date

July 20, 2017

Conditions
Plasma Cell Myeloma
Interventions
BIOLOGICAL

Daratumumab

Given IV

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT02944565 - Daratumumab in Treating Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter